

# UroGold

Li-SWT

Finally, advanced technology to treat women's sexual health issues. Because they deserve it.



Women's sexual health does not get enough attention in medical offices or research labs across the country

Doctors aren't asking, women aren't talking.

If conversations are happening women's symptoms are often dismissed many times due to lack of effective treatment options.

**Finally, women don't have to be ignored for their sexual concerns. Advanced technology is available to enhance and treat women's sexual health issues.**

“ The same old treatment strategies you have been using for decades may not be the best management strategies for everyone. ”



Sue W. Goldstein, BA, CCRC, AASECT-CSE  
ISSWSH President  
SAN DIEGO SEXUAL MEDICINE

## **SoftWave's UroGold — The best management strategy**

Research shows true shockwave therapy's effectiveness in sexual medicine treatment.

The best device is finally available for women with sexual health issues.



# RESEARCHED, TRUSTED & EFFECTIVE

## SoftWave's UroGold is a game changer in sexual health. There is a significant amount of evidence being published in academic journals worldwide documenting the efficacy and safety using true shockwave for many sexual health issues.

Available on ScienceDirect, Elsevier Masson France, EM Consult, ScienceDirect, Elsevier Masson France, EM Consult, ScienceDirect, Elsevier Masson France, EM Consult.

### Original article

#### Extracorporeal shock wave therapy for treating dyspareunia: A prospective, randomized, double-blind, placebo-controlled study

Karel Hruš<sup>1\*</sup>, Franješek Zuháček<sup>2</sup>, Michael Halačka<sup>3</sup>, Ivana Rakovicová<sup>4</sup>, Jakub Raković<sup>5</sup>, Václav Čmeláček<sup>6</sup>

**ARTICLE INFO**

**ABSTRACT**

**1. Introduction**

### 195 Retrospective Chart Review of Treatment Outcome Following Low-Intensity Shockwave Therapy for the Treatment of Vestibulodynia with Urogold 100™

#### 2. San Diego Sexual Medicine

**Introduction:** Genital pain disorders have devastating effects on a woman's quality of life, including social isolation. These disorders occur with high prevalence; more than 1/3 of women report pain during sexual activity, placing a significant financial burden on women and the healthcare system. Multiple medical treatments for dyspareunia are available to improve quality of life and decrease pain. However, many are invasive, involving pharmacotherapy/hormone therapy/surgical insertion/surgery, and are associated with significant morbidity. Low intensity shockwave therapy (LISWT) is a non-invasive, non-pharmacologic, non-hormonal, non-surgical, low-morbidity treatment strategy. FDA-cleared for pain amelioration in the US as non-significant risk in humans, Urogold 100™ is an electrohydraulic shockwave device that generates energy levels such as 0.10-0.12 mJ/mm<sup>2</sup> with a unique parabolic reflector.

Downloaded free from <http://www.urolsci.com> on Thursday, September 1, 2022, IP: 80.122.102.51

**Urological Science**  
Journal homepage: [www.urolsci.com](http://www.urolsci.com)

**Review Article**

## Potential Applications of Low-intensity Extracorporeal Shock-Wave Therapy in Urological Diseases via Activation of Tissue Resident Stem Cells

Binan Wang<sup>1</sup>, Amada S. Ross-McCubbin<sup>2</sup>, Kim Le, Galina Lyur, Tom Lu<sup>3</sup>  
<sup>1</sup>Department of Urology, School of Medicine, Oregon Health Division, University of California, San Francisco, CA, <sup>2</sup>Department of Urology, Temple University School of Medicine, Philadelphia, PA, USA, <sup>3</sup>Department of Urology, The Second Affiliated Hospital of Chongqing University School of Medicine, Chongqing University, China

**Abstract**

For many years, low-intensity extracorporeal shock-wave therapy (LISWT) has been clinically applied as a noninvasive therapeutic modality for urological diseases. The major corresponding biological molecular mechanism of LISWT involves the activation of stem cells. Recent studies have also shown that the combination treatment of LISWT treatment of erectile dysfunction (ED), energy transduction, bladder dysfunction, and stem cell therapy for these diseases are needed, highlighting the influence of L1-ESWT on the potential mechanisms, including the increased expression of stem cells and transmembrane growth factor (TGF-β) are described herein. LISWT treatment of LISWT and stem cell therapy is a promising strategy for urological diseases by which LISWT enhances the efficacy of stem cell therapy recommended for large-scale clinical application.

## Decrease in Opioid Use Post-Vestibulotomy Based on Pre-Operative Low Intensity Vestibular Shockwave Therapy (LISWT)

Irwine Goldstein  
Alvardo Hospital, United States of America

**1. Introduction**

Surgons performing complete vestibulotomy for neuro-proliferative vestibulodynia (NPV) need to consider acute pain relief in the early postoperative period and risks for persistent opioid use. One patient who failed multiple vestibular LISWT sessions to manage her pain eventually underwent vestibulotomy. We observed that post-operatively there was minimum hydrocodone use. Since a study showed that pre-operative LISWT improved wound healing and surgical outcome, it was hypothesized that LISWT promoted enhanced blood supply and angiogenesis through expression of vascular endothelial growth factor and nitric oxide synthesis, and via anti-inflammatory action down-regulating nociceptor factor. We wished to see if pre-operative LISWT would reduce post-operative opioid use. We compared opioid use post-op vestibulotomy in patients who had and had not undergone LISWT prior to surgery.

### Following Low-Intensity Shockwave Therapy for the Treatment of Vestibulodynia with Urogold 100™

**2. San Diego Sexual Medicine**

**Introduction:** Genital pain disorders have devastating effects on a woman's quality of life, including social isolation. These disorders occur with high prevalence; more than 1/3 of women report pain during sexual activity, placing a significant financial burden on women and the healthcare system. Multiple medical treatments for dyspareunia are available to improve quality of life and decrease pain. However, many are invasive, involving pharmacotherapy/hormone therapy/surgical insertion/surgery, and are associated with significant morbidity. Low intensity shockwave therapy (LISWT) is a non-invasive, non-pharmacologic, non-hormonal, non-surgical, low-morbidity treatment strategy. FDA-cleared for pain amelioration in the US as non-significant risk in humans, Urogold 100™ is an electrohydraulic shockwave device that generates energy levels such as 0.10-0.12 mJ/mm<sup>2</sup> with a unique parabolic reflector.

Downloaded free from <http://www.urolsci.com> on Thursday, September 1, 2022, IP: 80.122.102.51

**Human Stem Cells**

**Human Stem Cells**

**Human Stem Cells**

**Human Stem Cells**

**Human Stem Cells**

## Growing body of evidence showing benefits using Li-SWT

### Clinical Trials

### Randomized Trials

### Double Blind and Randomized

**Lumbo-Sacral Low Intensity Shock Wave Therapy for Persistent Genital Annual Disorder/Genito-Pelvic Dyspareunia Using the UroGold 100™ MTS (Yih et al., 2020, 2014 Annual Fall Scientific Meeting of Sexual Medicine Society of North America (SMSNA), Abstract No. 134)**

**Introduction:** Low intensity shockwave therapy (LISWT) was introduced to sexual medicine in 2010 as a non-invasive, non-pharmacologic, non-hormonal, non-surgical, low-morbidity treatment strategy for urological diseases. Ever since, sexual medicine clinicians have been broadening LISWT utilization for bothersome sexual health concerns. LISWT has been shown to be anti-inflammatory to such processes as radicularitis and is recommended for LISWT treatments of various pain conditions yields over 600 citations. Persistent genital annual disorder (PGAD) is a form of genito-pelvic dyspareunia (GPD), is a sexual medicine condition highly associated with despair, emotional lability, cataplexy and suicidality.

**Objective:** The objective of this chart review was to examine outcomes of a specific population of women with distressing PGAD/PGD suspected to be from radiolopathy of the sacral spinal nerve roots who underwent lumbo-sacral LISWT.

**Methods:** Patients presenting with PGAD/PGD suspected to be from radiolopathy of the sacral spinal nerve roots have the following: (i) abnormal lumbo-sacral MRI with degenerative disc disease, herniated nucleus pulposus, annular tear, facet cyst, and/or Tardis cyst; and (ii) consultation with a spine surgeon. Patients were selected for lumbo-sacral LISWT who had distressing symptoms of PGAD/PGD with underlying, unprovoked feelings of arousal, pain or other dyspareunia > 3 mos, who had either had minimally-invasive spine surgery (MISS) without full resolution of symptoms; had not been considered a candidate for MISS, or had chosen not to have lumbo-sacral surgery. Treatment involved using the UroGold 100™ MTS, OP155 parabolic probe, H3, energy density 0.06 - 0.10 mJ/mm<sup>2</sup> for 2-4 treatments, with 2100 - 4200 shocks to the left and right sacral and/or lumbar regions depending on the suspected site of pathology based on the MRI. The Patient Global Impression of Improvement (PGI-I) was administered at the second treatment visit and thereafter.

**Results:** Thirteen women (mean age 38 +/- 11 years) with various symptoms of PGAD/PGD were identified. 7 had MISS with improvement but not full resolution of their distressing symptoms and 6 did not have spine surgery. After treatments, 6/13 (52%) realized improvement of distressing symptoms selecting very much better, much better or somewhat better on the PGI-I. Four of the patients maintained improvement, reporting minimum PGAD/PGD distressing symptoms at 4-6 months following the last LISWT. The severest extent of temporary worsening of back pain was observed in 5 patients, noted for < 14 days post-treatment, that fully resolved in all patients.


**Conclusion:** While more research is needed, initial results are promising for this non-invasive, non-hormonal, non-pharmacologic shockwave energy-based strategy for a highly selected population of women with distressing PGAD/PGD secondary to suspected radiolopathy of sacral spinal nerve roots.

Research being done at leading universities and with physicians, physical therapists, and research scientists across the country

SoftWave UroGold  
Tissue Regeneration Technologies  
Li-SWT

High level quality shockwave evidence continues to mount including research led by experts who are experiencing impressive clinical results.

SoftWave's UroGold is being used in men's sexual health in leading institutions like UCLA, Baylor, Cleveland Clinic and others.



“ Shockwave research has been moving through the male sexual medicine world rapidly and we are excited to learn more about how this technology may aid in our female patients. We are hoping to gather more data on sexual pain conditions as well as improving arousal. The early indications are promising. ”

**Rachel S. Rubin, MD**

Board-certified urologist and sexual medicine specialist  
Fellowship training in sexual medicine for all genders.  
Education Chair for the International Society for the Study of Women's Sexual Health (ISSWSH)  
Associate editor for the journal Sexual Medicine Reviews



SoftWave TRT headquartered in Kennesaw, GA has been a leader and innovator in extracorporeal shockwave therapy since 2006. **SoftWave's UroGold Li-SWT** has been used and studied by major medical centers throughout the United States.



TRUSTED  
RESEARCHED  
EFFECTIVE



SoftWave's UroGold is a superior electrohydraulic Li-ESWT proven to be effective and safe for patients suffering from sexual health issues.



**UroGold**  
Li-SWT





UroGold Li-1000's energy absorption is wide and deep resulting in superior tissue propagation

# BETTER PHYSICS. BETTER DESIGN. BETTER OUTCOMES.

## It starts with a spark.

UroGold Li-SWT proprietary electrohydraulic device combines the best of both worlds. The acoustic unfocused shockwave allows the energy to be applied over a large surface area including a focused effect.

The **patented** parabolic reflector generates a primary and secondary wave that spreads the shockwave over a larger surface zone.



## Maximum tissue penetration to enhance the biological effects



Upon delivery, a cellular response is triggered activating the body's natural healing process resulting in:

**Increased blood supply** and subsequently angiogenesis

– the formation of new blood vessels to increase blood flow into the treated area.

The proliferation of muscle cells to restore tissue elasticity and support tissue remodeling and regeneration

Activation of endogenous growth factors and more.



# How does it help women with sexual health issues?

[Schedule a call today to learn more](#)

## 7. BIOLOGIC ACTION OF LISWT IN TISSUES

Physiological Effect	Based on	Study Source
Shear stress	Shockwave exert a "cavitation effect" (inside and outside of cells) inducing localized stress on cell membranes that resembles shear stress	Maisonhaute E, Prado C, White PC. Surface acoustic cavitation understood via nanosecond electrochemistry. <i>Ultrason Sonochem</i> 2002;
NO synthesis	Shockwave cause nonenzymatic nitric oxide synthesis from L-arginine and hydrogen peroxide.	Gotte G, Amello E, Russo S. Short-time non-enzymatic nitric oxide synthesis from L-arginine and hydrogen peroxide Induced by shock waves treatment. <i>FEBS Lett</i> 2002.
VEGF and flt-1 upregulation	SW upregulates VEGF and its receptor, Flt-1, in endothelial cells in vitro and VEGF in the ischemic myocardium in vivo.	Nishida T, Shimokawa H, Oi K, Tatewaki H. Extracorporeal cardiac shock wave therapy markedly ameliorates ischemia-induced myocardial dysfunction in pigs in vivo. <i>Circulation</i> 2004
Endothelial Progenitor Cells recruitment	Shock Wave Therapy recruits systemically infused Endothelial Progenitor Cells on a rat model of chronic limb ischemia.	Aicher A, Heeschen C, Sasaki K. Low-Energy Shock Wave for Enhancing Recruitment of Endothelial Progenitor Cells - A New Modality to Increase Efficacy of Cell Therapy in Chronic Hind Limb Ischemia. <i>Circulation</i> . 2006
Anti-inflammatory	Modulation of neuronal NOS catalytic activity, NO production, NF-κB activation, Isoform NOS and TNF-alpha mRNA expression	Ciampaa AR, Marlinghouse E, Suzukia H. Nitric oxide mediates anti-inflammatory action of extracorporeal shock waves. <i>FEBS Lett</i> 2005
Neovascularization	SW therapy induces neovascularization at tendon via upregulation of endothelial nitric oxide synthesis, VEGF, and proliferating cell antigen.	Wang CJ, Wang FS, Yang KD. Shock wave therapy induces neovascularization at the tendon-bone junction. A study in rabbits. <i>J Orthop Res</i> 2003
Local perfusion increased	Myocardial perfusion in the ischemic myocardium was improved only where the SW's were applied.	Fukumoto Y, Shimokawa H et al 2006
Vasodilatation	Shockwaves acutely reduces arterial perfusion pressure on artificially perfused rabbit	Seemann O, Rassweiler J, Chvapil M. The effect of single shock waves on the vascular system of artificially perfused rabbit kidneys. <i>J Stone Dis</i> . 1993


# UroGold — the best choice.

Li-SWT




**UroGold LISWT delivers a TRUE extracorporeal electrohydraulic shockwave that penetrates wider and deeper. Flexible elastic membrane adapts optimally to the treatment area.**

**Radial devices deliver a pressure wave, NOT a shockwave.**



Shockwaves are acoustic pulses with high positive pressure, **fast and steep rise time** followed by comparatively **small negative pressure** (tensile wave).



Radial pressure waves are acoustic **pneumatic pulses** with a **low steeping effect, slow rise time** with comparatively **large negative pressure** (tensile wave).

**Choose UroGold Li-SWT and get better results**



# It's time for women to get the treatment they deserve.

- ▶ Quality research is available
- ▶ Evidence is growing rapidly
- ▶ Trained health practitioners are using it in the U.S.
- ▶ Women are looking for non-invasive solutions
- ▶ Women have a right to pain-free sexual activity and better sex lives for them and their partners



The energy to make things happen fits right in your hand

- 🕒 Accelerated healing in less time
- 🕒 Quick 10-15 minute treatment times  
Non-invasive and effective  
No side effects, pain-free
- 🔍 Long term solution—  
Treats the cause, not only the symptoms
- ✅ Patented technology and protocols
- ✅ Versatility and innovation that allows you to treat many sexual health conditions

**UroGold**  
Li-SWT

A breakthrough in healthcare that is the solution to treat women with the potential to substantially grow your sexual health practice

 **SoftWave**  
Tissue Regeneration Technologies

# Why wait any longer to add quality care that women are searching for?

Improve your productivity and profitability by offering UroGold100 Li-SWT

## UroGold

Li-SWT

RESEARCHED TRUSTED EFFECTIVE

[www.softwavetr.com](http://www.softwavetr.com)

[info@softwavetr.com](mailto:info@softwavetr.com)

Schedule a call today



Patent No. US 11,389,372 B2  
& Patents pending



FOR:

- Improved blood supply
- Activation of connective tissue
- Temporary pain relief
- Treatment of chronic diabetic foot ulcers